On October 14, 2025 reported $JNJ (-0.67%)
strong quarterly results. Earnings per share (EPS) were $2.80, above expectations of $2.76, while revenue of $23.993 billion was also 1% above estimates. Year-on-year, EPS was up 16% and revenue up 7%, underscoring the company's growing strength. There was also a slight 1% increase quarter-on-quarter.
These results show that Johnson & Johnson, supported by strong pharmaceutical and medical business, continues to grow despite economic challenges.